TScan Therapeutics viewed as more attractive investment, better earnings despite lower revenue.

TScan Therapeutics is viewed as a more attractive investment than Sorrento Therapeutics, with a consensus price target of $12.00 and stronger institutional ownership. TScan reports better earnings despite lower revenue. Sorrento, focused on next-generation treatments for cancer and infectious diseases, has a significantly higher net loss. Similarly, Sensus Healthcare outperforms Sigyn Therapeutics on financial metrics, while Quince Therapeutics shows less volatility compared to Pluri Inc.

October 09, 2024
3 Articles